POAI

MKT CAP:$4M

Predictive Oncology Inc.

Market Cap

$4M

Healthcare·Medical - Instruments & Supplies·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$4.29-$2.80 (-39.49%)

Apr 21, 2026

Company Details

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble...

CEO

Raymond F. Vennare

IPO Date

May 3, 2010

Website

www.predictive-oncology.com

Key Metrics TTM

Revenue

$1M

-16.5% YoY

Net Income

-$87M

EPS (Diluted)

-$109.57

Free Cash Flow

-$11M

Revenue / Share

$1.79

Gross Margin

48.6%

Operating Margin

-982.5%

Net Margin

-6759.8%

FCF Margin

-854.9%

P/S

2.8x

P/E

—

Earnings Reports

FY 2025

Mar 31, 2026

$125.3KEPS -$13.37

Q3 2025

Nov 14, 2025

$3.6KEPS -$107.25

Q2 2024

Aug 13, 2024

$278.7K-43.1%EPS -$0.68

Q4 2023

Mar 28, 2024

$335.0K-7.8%EPS -$0.86

Q3 2023

Nov 13, 2023

$676.6K+48.4%EPS -$0.78

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 20	$480.8K	$305.6K	-$6M
Q4 20	$293.8K	$199.7K	-$13M
Q1 21	$280.3K	$182.6K	-$4M
Q2 21	$350.2K	$207.3K	-$3M
Q3 21	$313.7K	$203.5K	-$5M
Q4 21	$476.5K	$340.3K	-$9M
Q1 22	$314.6K	$205.1K	-$3M
Q2 22	$371.6K	$237.5K	-$11M
Q3 22	$455.8K	$347.7K	-$4M
Q4 22	$363.5K	$210.0K	-$8M
Q1 23	$239.9K	$119.8K	-$3M
Q2 23	$490.1K	$330.3K	-$4M
Q3 23	$676.6K	$578.8K	-$3M
Q4 23	$335.0K	-$71.3K	-$4M
Q2 24	$278.7K	$125.8K	-$3M
Q3 25	$3.6K	-$4.7K	-$3M

Valuation

Quarter	P/S	P/E
Q3 20	130.6x	—
Q4 20	150.0x	—
Q1 21	471.3x	—
Q2 21	599.0x	—
Q3 21	1046.1x	—
Q4 21	686.8x	—
Q1 22	719.5x	—
Q2 22	321.0x	—
Q3 22	269.2x	—
Q4 22	289.4x	—
Q1 23	260.6x	—
Q2 23	217.9x	—
Q3 23	109.0x	—
Q4 23	113.5x	—
Q2 24	43.9x	—
Q3 25	126.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 20	-$3M	-$3M
Q4 20	-$2M	-$3M
Q1 21	-$3M	-$4M
Q2 21	-$2M	-$2M
Q3 21	-$3M	-$3M
Q4 21	-$4M	-$4M
Q1 22	-$3M	-$3M
Q2 22	-$3M	-$4M
Q3 22	-$3M	-$3M
Q4 22	-$3M	-$3M
Q1 23	-$3M	-$3M
Q2 23	-$4M	-$4M
Q3 23	-$3M	-$3M
Q4 23	-$3M	-$3M
Q2 24	-$3M	-$3M
Q3 25	-$2M	-$2M

Capital Expenditures

Quarter	CapEx
Q3 20	$116.2K
Q4 20	$200.7K
Q1 21	$393.1K
Q2 21	$240.7K
Q3 21	$131.5K
Q4 21	$195.9K
Q1 22	$80.2K
Q2 22	$188.2K
Q3 22	$128.3K
Q4 22	$63.6K
Q1 23	$46.6K
Q2 23	$259.1K
Q3 23	$3.9K
Q4 23	$7.3K
Q2 24	$6.5K
Q3 25	$3

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 20	-8.0%	+53.5%
Q4 20	-15.5%	+296.1%
Q1 21	-5.0%	+8.7%
Q2 21	+91.6%	-25.4%
Q3 21	-34.8%	-4.6%
Q4 21	+62.2%	-29.6%
Q1 22	+12.2%	-8.1%
Q2 22	+6.1%	+269.6%
Q3 22	+45.3%	-21.0%
Q4 22	-23.7%	-7.8%
Q1 23	-23.7%	-0.6%
Q2 23	+31.9%	-59.2%
Q3 23	+48.4%	-25.5%
Q4 23	-7.8%	-53.9%
Q2 24	+16.2%	-6.4%
Q3 25	-99.3%	-26.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 20	$0	0.0%
Q4 20	$0	0.0%
Q1 21	$0	0.0%
Q2 21	$0	0.0%
Q3 21	$0	0.0%
Q4 21	$0	0.0%
Q1 22	$0	0.0%
Q2 22	$39.4K	10.6%
Q3 22	$121.0K	26.5%
Q4 22	$0	0.0%
Q1 23	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$111.3K	16.4%
Q4 23	$95.8K	28.6%
Q2 24	$0	0.0%
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q3 20	$36.6K	$2M	$121.5K
Q4 20	$144.9K	$2M	$66.0K
Q1 21	$93.6K	$3M	$114.6K
Q2 21	$49.7K	$2M	$159.8K
Q3 21	$91.0K	$2M	$172.9K
Q4 21	$81.5K	$4M	$327.2K
Q1 22	$68.2K	$2M	$304.5K
Q2 22	$33.4K	$2M	$271.0K
Q3 22	$15.2K	$3M	$333.4K
Q4 22	$203.6K	$3M	$450.0K
Q1 23	—	$2M	$370.2K
Q2 23	—	$2M	$429.1K
Q3 23	—	$2M	$334.4K
Q4 23	$33.5K	$2M	$375.5K
Q2 24	—	$2M	$284.4K
Q3 25	—	$3M	$133.5K

Revenue Segments

Quarter	Helomics Segment	Skyline	Soluble	Z PREDICTA
Q3 20	$9.7K	$471.1K	—	—
Q4 20	$30.3K	$260.6K	—	—
Q1 21	$2.0K	$264.3K	$14.1K	—
Q2 21	$7.2K	$306.1K	$34.9K	—
Q3 21	$2.2K	$282.7K	$27.7K	—
Q4 21	$2.1K	$316.7K	$156.7K	—
Q1 22	$3.6K	$279.3K	$12.9K	$18.3K
Q2 22	$84	$276.9K	$22.2K	$71.9K
Q3 22	$1.8K	$253.8K	$29.4K	$170.8K
Q4 22	$854	$253.6K	$17.7K	$91.3K

Revenue by Geography

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$25M	$0	$25M
Q2 22	$28M	$0	$28M
Q3 22	$25M	$0	$25M
Q4 22	$22M	$0	$22M
Q1 23	$19M	$0	$19M
Q2 23	$15M	$0	$15M
Q3 23	$12M	$0	$12M
Q4 23	$9M	$0	$9M
Q1 24	$5M	$0	$5M
Q2 24	$5M	$0	$5M
Q3 24	$3M	$0	$3M
Q4 24	$734.7K	$0	$734.7K
Q1 25	$3M	$0	$3M
Q2 25	$506.1K	$0	$506.1K
Q3 25	$181.7K	$0	$181.7K
Q4 25	$11M	$0	$11M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 20	751K	+52.7%	+377.5%
Q4 20	900K	+19.7%	+381.4%
Q1 21	2M	+102.9%	+650.3%
Q2 21	3M	+41.3%	+424.3%
Q3 21	3M	+26.8%	+335.3%
Q4 21	3M	+0.4%	+265.1%
Q1 22	3M	+0.2%	+80.3%
Q2 22	4M	+9.1%	+39.2%
Q3 22	4M	+9.2%	+19.8%
Q4 22	4M	+0.4%	+19.9%
Q1 23	4M	+0.8%	+20.5%
Q2 23	4M	+0.7%	+11.3%
Q3 23	4M	+0.9%	+2.9%
Q4 23	4M	+0.8%	+3.2%
Q2 24	5M	+14.8%	+17.6%
Q3 25	724K	-84.5%	-81.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 20	$16.6K	29
Q4 20	$13.4K	22
Q1 21	$12.7K	22
Q2 21	$15.9K	22
Q3 21	$14.3K	22
Q4 21	$15.9K	30
Q1 22	$10.5K	30
Q2 22	$12.4K	30
Q3 22	$15.2K	30
Q4 22	$11.7K	31
Q1 23	$7.7K	31
Q2 23	$15.8K	31
Q3 23	$21.8K	31
Q4 23	$9.9K	34
Q2 24	$8.2K	34
Q3 25	$157	23

Revenue / Employee